vs
Gaming & Leisure Properties, Inc.（GLPI）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Gaming & Leisure Properties, Inc.的1.8倍（$772.1M vs $420.0M），Gaming & Leisure Properties, Inc.净利率更高（57.0% vs 12.7%，领先44.3%），Gaming & Leisure Properties, Inc.同比增速更快（6.3% vs 5.9%），过去两年Revvity的营收复合增速更高（9.0% vs 5.0%）
博彩与休闲地产公司（GLPI）是一家专注于赌场物业的房地产投资信托（REIT），总部位于宾夕法尼亚州怀奥米辛。公司于2013年11月从宾州国民娱乐分拆成立，目前持有62处赌场物业，全部对外出租给其他企业运营。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
GLPI vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.8倍
$420.0M
营收增速更快
GLPI
高出0.4%
5.9%
净利率更高
GLPI
高出44.3%
12.7%
两年增速更快
RVTY
近两年复合增速
5.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $420.0M | $772.1M |
| 净利润 | $239.4M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 79.4% | 14.5% |
| 净利率 | 57.0% | 12.7% |
| 营收同比 | 6.3% | 5.9% |
| 净利润同比 | 40.5% | 3.9% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GLPIRVTY
| Q1 26 | $420.0M | — | ||
| Q4 25 | $407.0M | $772.1M | ||
| Q3 25 | $397.6M | $698.9M | ||
| Q2 25 | $394.9M | $720.3M | ||
| Q1 25 | $395.2M | $664.8M | ||
| Q4 24 | $389.6M | $729.4M | ||
| Q3 24 | $385.3M | $684.0M | ||
| Q2 24 | $380.6M | $691.7M |
净利润GLPIRVTY
| Q1 26 | $239.4M | — | ||
| Q4 25 | $275.4M | $98.4M | ||
| Q3 25 | $241.2M | $46.7M | ||
| Q2 25 | $151.4M | $53.9M | ||
| Q1 25 | $165.2M | $42.2M | ||
| Q4 24 | $223.6M | $94.6M | ||
| Q3 24 | $184.7M | $94.4M | ||
| Q2 24 | $208.3M | $55.4M |
毛利率GLPIRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% |
营业利润率GLPIRVTY
| Q1 26 | 79.4% | — | ||
| Q4 25 | 89.3% | 14.5% | ||
| Q3 25 | 84.8% | 11.7% | ||
| Q2 25 | 61.3% | 12.6% | ||
| Q1 25 | 65.5% | 10.9% | ||
| Q4 24 | 79.1% | 16.3% | ||
| Q3 24 | 70.4% | 14.3% | ||
| Q2 24 | 77.1% | 12.4% |
净利率GLPIRVTY
| Q1 26 | 57.0% | — | ||
| Q4 25 | 67.6% | 12.7% | ||
| Q3 25 | 60.7% | 6.7% | ||
| Q2 25 | 38.4% | 7.5% | ||
| Q1 25 | 41.8% | 6.4% | ||
| Q4 24 | 57.4% | 13.0% | ||
| Q3 24 | 47.9% | 13.8% | ||
| Q2 24 | 54.7% | 8.0% |
每股收益（稀释后）GLPIRVTY
| Q1 26 | — | — | ||
| Q4 25 | $0.96 | $0.86 | ||
| Q3 25 | $0.85 | $0.40 | ||
| Q2 25 | $0.54 | $0.46 | ||
| Q1 25 | $0.60 | $0.35 | ||
| Q4 24 | $0.79 | $0.77 | ||
| Q3 24 | $0.67 | $0.77 | ||
| Q2 24 | $0.77 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $274.5M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $5.0B | $7.3B |
| 总资产 | $13.8B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GLPIRVTY
| Q1 26 | $274.5M | — | ||
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $560.8M | $1.2B | ||
| Q3 24 | $560.8M | $1.2B | ||
| Q2 24 | $560.8M | $2.0B |
总债务GLPIRVTY
| Q1 26 | — | — | ||
| Q4 25 | $7.2B | — | ||
| Q3 25 | $7.2B | — | ||
| Q2 25 | $6.9B | — | ||
| Q1 25 | $6.9B | — | ||
| Q4 24 | $7.7B | — | ||
| Q3 24 | $7.4B | — | ||
| Q2 24 | $6.6B | — |
股东权益GLPIRVTY
| Q1 26 | $5.0B | — | ||
| Q4 25 | $4.6B | $7.3B | ||
| Q3 25 | $4.6B | $7.4B | ||
| Q2 25 | $4.6B | $7.6B | ||
| Q1 25 | $4.2B | $7.6B | ||
| Q4 24 | $4.3B | $7.7B | ||
| Q3 24 | $4.3B | $7.9B | ||
| Q2 24 | $4.1B | $7.9B |
总资产GLPIRVTY
| Q1 26 | $13.8B | — | ||
| Q4 25 | $12.9B | $12.2B | ||
| Q3 25 | $12.8B | $12.1B | ||
| Q2 25 | $12.5B | $12.4B | ||
| Q1 25 | $12.1B | $12.4B | ||
| Q4 24 | $13.1B | $12.4B | ||
| Q3 24 | $12.7B | $12.8B | ||
| Q2 24 | $11.8B | $13.4B |
负债/权益比GLPIRVTY
| Q1 26 | — | — | ||
| Q4 25 | 1.56× | — | ||
| Q3 25 | 1.57× | — | ||
| Q2 25 | 1.51× | — | ||
| Q1 25 | 1.63× | — | ||
| Q4 24 | 1.81× | — | ||
| Q3 24 | 1.74× | — | ||
| Q2 24 | 1.60× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流GLPIRVTY
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $182.0M | ||
| Q3 25 | $240.3M | $138.5M | ||
| Q2 25 | $293.4M | $134.3M | ||
| Q1 25 | $252.5M | $128.2M | ||
| Q4 24 | $1.1B | $174.2M | ||
| Q3 24 | $270.4M | $147.9M | ||
| Q2 24 | $252.1M | $158.6M |
自由现金流GLPIRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | $161.8M | ||
| Q3 25 | $183.0M | $120.0M | ||
| Q2 25 | $272.3M | $115.5M | ||
| Q1 25 | $239.6M | $112.2M | ||
| Q4 24 | $1.1B | $149.8M | ||
| Q3 24 | $261.5M | $125.6M | ||
| Q2 24 | $245.0M | $136.6M |
自由现金流率GLPIRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 21.0% | ||
| Q3 25 | 46.0% | 17.2% | ||
| Q2 25 | 69.0% | 16.0% | ||
| Q1 25 | 60.6% | 16.9% | ||
| Q4 24 | 275.3% | 20.5% | ||
| Q3 24 | 67.9% | 18.4% | ||
| Q2 24 | 64.4% | 19.7% |
资本支出强度GLPIRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 2.6% | ||
| Q3 25 | 14.4% | 2.6% | ||
| Q2 25 | 5.3% | 2.6% | ||
| Q1 25 | 3.3% | 2.4% | ||
| Q4 24 | 0.0% | 3.4% | ||
| Q3 24 | 2.3% | 3.3% | ||
| Q2 24 | 1.9% | 3.2% |
现金转化率GLPIRVTY
| Q1 26 | — | — | ||
| Q4 25 | 4.10× | 1.85× | ||
| Q3 25 | 1.00× | 2.97× | ||
| Q2 25 | 1.94× | 2.49× | ||
| Q1 25 | 1.53× | 3.03× | ||
| Q4 24 | 4.80× | 1.84× | ||
| Q3 24 | 1.46× | 1.57× | ||
| Q2 24 | 1.21× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GLPI
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
